ADMA biotech catalysts & pipeline

ADMA BIOLOGICS INC · Data as of 2026-10-25

Upcoming catalysts

SG-001 — FDA meeting

by year-end

ADMA continues to advance plasma collection optimization, potency assay development and preclinical activities supporting planned conformance lot production during the second half of 2026, ahead of the anticipated submission of its pre-Investigational New Drug (IND) meeting package to the U.S. Food and Drug Administration by year-end.

Source filing

immune globulin intravenous, human – slra — Conference presentation

Nov 12–Nov 16

The study's findings demonstrated that patients experienced statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use and corticosteroid use following ASCENIV administration, and the findings have been submitted as an abstract to the November 2026 American College of Allergy, Asthma & Immunology ("ACAAI") Annual Scientific Meeting.

Source filing

Explore the free biotech catalyst calendar